A biotech buyer can now begin due diligence with a conversational prompt rather than a list of blue links. A sourcing lead might ask an AI research tool to identify CDMOs in the DACH region with validated commercial-scale mRNA manufacturing and mention experience relevant to an FDA 510(k) context.
A different prompt may ask whether a company works with CRISPR-Cas9 delivery, while another may compare manufacturing support for a GLP-1 program. The SEO problem is not to force a model to recommend the company.
It is to make public facts easy to find, distinguish, and verify so an AI-generated answer has a better chance of representing the organization accurately. That means tracing real prompt journeys, clarifying what the entity is and does, strengthening the pages that are eligible to support an answer, correcting material errors at their source, and measuring what actually changes in AI outputs and referred visits.
In biotech, ambiguity has a high cost: a model can merge a research topic with a service, confuse an old capability with a current one, or repeat an unsupported claim. A decision-useful program therefore treats accuracy and source quality as the core of AI SEO, with visibility as the result to observe rather than a guarantee to sell.